ELX-02
EL-014
Phase 2 small_molecule completed
Quick answer
ELX-02 for Alport Syndrome is a Phase 2 program (small_molecule) at Eloxx Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eloxx Pharmaceuticals
- Indication
- Alport Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed